another one with an approved drug, ariad, who had a new drug on the market.hich patients it might be used best in and there was a big mover in. pharmas. brist bristol-myers. they'll have a lot more data at the meeting they'll be looking for. whether they turn that decline down after they got that down-grade, melissa. >> meg, thanks for that. >> one of the things you see, most of those names peaked in march. >> the big space bio tech is interested in is oncology drugs. the cancer drugs. the real growth opportunities. the thing about playing any one of these, they play at astonishing modules. there are actually a lot of companies not trading in obscene multiples, one name that comes to mind is cell jean. the way to capture those plays without taking the risk. would be on the names of incyte and clovis. one way is to play ibb. take advantage of the fact that options prices are up. jefferys is holding one. i would simply sell a put spread on ibb. the one that i'm looking at specifically is the july 235, 225 put spread. sell for $10 and buy for $6 to protect yours